Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Artivion, Inc. (AORT)
USD23.11
-0.92 (-3.83%)
US NYSE Healthcare Medical - Devices
Address
1655 Roberts Boulevard N.W. 30144
Kennesaw, GA, US
Kennesaw, GA, US
CEO
James Patrick Mackin
Website
artivion.com
IPO
1993-02-12
CIK 784199 ISIN US2289031005
Also trades on
New York Stock Exchange · AORT (USD)
New York Stock Exchange · CRY (USD)
Description
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD23.11
-0.92 (-3.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
760.8K
Beta
1.25
Float Shares
45.40M
Free Float %
93.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.98% | -15.42% | -40.11% | -36.89% | -49.33% | -49.35% | -20.10% | +51.97% | -19.85% | +96.93% | +188.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
23.11
Low
51.00
+120.7%
Consensus
53.00
+129.3%
Median
53.00
+129.3%
High
55.00
+138.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | +1 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
55.00
+138.0%
|
| Last Year | 4 |
50.25
+117.4%
|
| All Time | 9 |
39.33
+70.2%
|
Quality scores
Altman Z-Score
2.43
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
2 / 5
Medium
ROA Score
3 / 5
Medium
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+13.6% ★ Q1'26: +17.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+165.6% ★ Q1'26: +339.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-6.1% Q1'26: -5.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+6.1% Q1'26: +6.4% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+2.6% Q1'26: +4.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+13.2% Q1'26: +17.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×5.94× Q1'26: 4.67× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
145.90M
est: 146.11M (-0.1%)
|
180.38M
est: 182.28M (-1.0%)
|
189.70M
est: 185.07M (+2.5%)
|
262.84M
est: 262.09M (+0.3%)
|
276.22M
est: 277.35M (-0.4%)
|
253.23M
est: 251.78M (+0.6%)
|
298.84M
est: 297.24M (+0.5%)
|
313.79M
est: 314.34M (-0.2%)
|
354.00M
est: 376.97M (-6.1%)
|
388.54M
est: 392.06M (-0.9%)
|
441.33M
est: 441.77M (-0.1%)
|
487.56M
487.17M – 487.95M
+10.4% YoY
|
541.26M
539.99M – 542.54M
+11.0% YoY
|
601.23M
591.46M – 611.00M
+11.1% YoY
|
677.90M
669.50M – 686.55M
+12.8% YoY
|
763.90M
754.43M – 773.65M
+12.7% YoY
|
| EBITDA |
11.22M
est: 13.32M (-15.8%)
|
25.29M
est: 16.61M (+52.2%)
|
18.18M
est: 16.87M (+7.7%)
|
30.21M
est: 23.89M (+26.4%)
|
34.85M
est: 25.28M (+37.8%)
|
20.24M
est: 22.95M (-11.8%)
|
26.04M
est: 27.09M (-3.9%)
|
25.68M
est: 28.65M (-10.4%)
|
26.79M
est: 36.74M (-27.1%)
|
50.97M
est: 38.21M (+33.4%)
|
49.20M
est: 43.06M (+14.3%)
|
47.52M
47.48M – 47.56M
+10.4% YoY
|
52.75M
52.63M – 52.88M
+11.0% YoY
|
58.60M
57.65M – 59.55M
+11.1% YoY
|
66.07M
65.25M – 66.91M
+12.8% YoY
|
74.45M
73.53M – 75.40M
+12.7% YoY
|
| EBIT |
5.35M
est: 2.77M (+93.5%)
|
16.91M
est: 3.45M (+389.6%)
|
8.44M
est: 3.51M (+140.8%)
|
12.11M
est: 4.96M (+144.0%)
|
16.53M
est: 5.25M (+214.7%)
|
-476.0K
est: 4.77M (-110.0%)
|
2.06M
est: 5.63M (-63.4%)
|
3.24M
est: 5.95M (-45.6%)
|
3.71M
est: 11.85M (-68.7%)
|
26.76M
est: 12.33M (+117.1%)
|
26.75M
est: 13.89M (+92.6%)
|
15.33M
15.32M – 15.34M
+10.4% YoY
|
17.02M
16.98M – 17.06M
+11.0% YoY
|
18.90M
18.59M – 19.21M
+11.1% YoY
|
21.31M
21.05M – 21.58M
+12.8% YoY
|
24.02M
23.72M – 24.32M
+12.7% YoY
|
| Net Income |
4.01M
est: 3.75M (+6.8%)
|
10.78M
est: 12.34M (-12.6%)
|
3.70M
est: 10.73M (-65.5%)
|
-3.81M
est: -750.2K (-407.2%)
|
1.72M
est: 3.75M (-54.1%)
|
-16.68M
est: -16.57M (-0.7%)
|
-14.83M
est: 2.78M (-633.9%)
|
-19.19M
est: -27.34M (+29.8%)
|
-30.69M
est: -9.53M (-222.0%)
|
-13.36M
est: 393.1K (-3,498.4%)
|
9.77M
est: 10.10M (-3.2%)
|
7.33M
7.21M – 7.45M
-27.4% YoY
|
22.47M
22.11M – 22.84M
+206.5% YoY
|
42.59M
35.70M – 45.56M
+89.5% YoY
|
56.12M
55.22M – 57.05M
+31.8% YoY
|
74.04M
72.85M – 75.27M
+31.9% YoY
|
| SGA |
74.93M
est: 79.27M (-5.5%)
|
91.55M
est: 98.89M (-7.4%)
|
101.21M
est: 100.41M (+0.8%)
|
140.57M
est: 142.19M (-1.1%)
|
143.01M
est: 150.47M (-5.0%)
|
141.14M
est: 136.60M (+3.3%)
|
169.77M
est: 161.26M (+5.3%)
|
157.44M
est: 170.54M (-7.7%)
|
208.98M
est: 198.84M (+5.1%)
|
192.38M
est: 206.79M (-7.0%)
|
212.72M
est: 233.02M (-8.7%)
|
257.17M
256.96M – 257.38M
+10.4% YoY
|
285.50M
284.82M – 286.17M
+11.0% YoY
|
317.13M
311.97M – 322.28M
+11.1% YoY
|
357.57M
353.13M – 362.13M
+12.8% YoY
|
402.93M
397.93M – 408.07M
+12.7% YoY
|
| EPS |
0.14
est: 0.09 (+55.6%)
|
0.33
est: 0.30 (+11.5%)
|
0.11
est: 0.26 (-57.3%)
|
-0.11
est: -0.02 (-511.1%)
|
0.05
est: 0.09 (-48.9%)
|
-0.44
est: -0.40 (-10.7%)
|
-0.38
est: 0.07 (-670.0%)
|
-0.48
est: -0.66 (+26.8%)
|
-0.75
est: -0.20 (-271.2%)
|
-0.32
est: 0.01 (-3,940.2%)
|
0.22
est: 0.21 (+2.8%)
|
0.16
0.15 – 0.16
-27.4% YoY
|
0.48
0.47 – 0.48
+206.5% YoY
|
0.84
0.76 – 0.97
+75.6% YoY
|
1.19
1.17 – 1.21
+42.2% YoY
|
1.57
1.54 – 1.60
+31.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
28.39M
OE per share TTM
0.61
Owner's Yield
1.67%
Maintenance CapEx ratio
286.93%
Maint CapEx / Avg PPE
22.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 7.22M | 17.90% | — | — | — | — | HC | Delaware | 2023-01-20 | ↗ |
| 2 | Wasatch Advisors, Inc. 87-0319391 | 2.79M | 7.10% | 2.79M | — | 2.79M | — | IA | — | 2022-02-11 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 2.65M | 6.74% | — | — | 2.55M | 98.3K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 4 | Joseph Edelman | 2.38M | 5.80% | — | 2.38M | — | 2.38M | IN | Delaware | 2024-03-11 | ↗ |
| 5 | Perceptive Advisors LLC | 2.38M | 5.80% | — | 2.38M | — | 2.38M | IA | Delaware | 2024-03-11 | ↗ |
| 6 | Perceptive Life Sciences Master Fund, Ltd. | 2.38M | 5.80% | — | 2.38M | — | 2.38M | CO | Delaware | 2024-03-11 | ↗ |
| 7 | Wellington Group Holdings LLP | 2.28M | 5.64% | — | 2.19M | — | — | HC | Delaware | 2023-02-06 | ↗ |
| 8 | Wellington Investment Advisors Holdings LLP | 2.28M | 5.64% | — | 2.19M | — | — | HC | Delaware | 2023-02-06 | ↗ |
| 9 | Wellington Management Group LLP | 2.28M | 5.64% | — | 2.19M | — | — | HC | Massachusetts | 2023-02-06 | ↗ |
| 10 | Macquarie Group Limited | 2.22M | 5.64% | — | — | — | — | HC | — | 2022-02-14 | ↗ |
| 11 | Macquarie Investment Management Business Trust | 2.22M | 5.64% | 2.20M | — | 2.20M | — | IA | — | 2022-02-14 | ↗ |
| 12 | Macquarie Management Holdings Inc | 2.22M | 5.64% | 2.20M | — | 2.20M | — | HC | — | 2022-02-14 | ↗ |
| 13 | Morgan Stanley | 2.19M | 5.40% | 13.00 | 375.2K | — | 2.19M | HC, CO | — | 2023-02-08 | ↗ |
| 14 | Wellington Management Company LLP | 2.18M | 5.41% | — | 2.14M | — | — | IA | Delaware | 2023-02-06 | ↗ |
| 15 | Alexis P. Michas | 2.09M | 5.20% | — | 2.09M | — | 2.09M | IN | United States | 2022-09-26 | ↗ |
| 16 | John A. Bartholdson | 2.09M | 5.20% | — | 2.09M | — | 2.09M | IN | United States | 2022-09-26 | ↗ |
| 17 | Juniper Investment Company, LLC | 2.09M | 5.20% | — | 2.09M | — | 2.09M | IA | Delaware | 2022-09-26 | ↗ |
| 18 | Macquarie Bank Limited | 2.04M | 5.25% | — | — | — | — | CO | — | 2021-02-12 | ↗ |
| 19 | Macquarie Investment Management Holdings Inc | 2.04M | 5.25% | 2.03M | — | 2.03M | — | HC | — | 2021-02-12 | ↗ |
| 20 | (. | 2.01M | 5.57% | 1.91M | — | 2.01M | — | IA | Delaware Limited Partnership | 2018-02-09 | ↗ |
| 21 | SMALLCAP World Fund, Inc. | 1.96M | 5.30% | — | — | — | — | IV | Maryland | 2019-02-14 | ↗ |
| 22 | 1,888,879 | 1.89M | 5.23% | 1.89M | — | 1.89M | — | IA | Sydney, New South Wales Australia | 2018-02-14 | ↗ |
| 23 | Holdings Inc. and Macquarie Investment Management Business Trust whose individual holdings are shown | 1.89M | 5.23% | — | — | — | — | HC | Sydney, New South Wales Australia | 2018-02-14 | ↗ |
| 24 | Investment Management Business Trust whose individual holdings are shown on the following forms. | 1.89M | 5.23% | — | — | — | — | CO | Sydney, New South Wales Australia | 2018-02-14 | ↗ |
| 25 | Trust | 1.89M | 5.23% | 1.89M | — | 1.89M | — | HC | Sydney, New South Wales Australia | 2018-02-14 | ↗ |
| 26 | Capital Research Global Investors ** | 1.54M | 4.10% | 1.54M | — | — | — | IA | Delaware | 2020-02-14 | ↗ |
| 27 | Morgan Stanley Smith Barney LLC | 1.54M | 4.10% | — | — | — | 1.54M | BD | Delaware. | 2019-02-12 | ↗ |
| 28 | Juniper HF Investors II, LLC | 1.47M | 3.70% | — | 1.47M | — | 1.47M | PN | Delaware | 2022-09-26 | ↗ |
| 29 | Juniper Targeted Opportunity Fund, L.P. | 1.47M | 3.70% | 1.47M | — | 1.47M | — | PN | Delaware | 2022-09-26 | ↗ |
| 30 | Juniper Targeted Opportunities, L.P. | 606.8K | 1.50% | 606.8K | — | 606.8K | — | PN | Delaware | 2022-09-26 | ↗ |
| 31 | Juniper Targeted Opportunity Investors, LLC | 606.8K | 1.50% | — | 606.8K | — | 606.8K | PN | Delaware | 2022-09-26 | ↗ |
| 32 | Juniper HF Investors, LLC | 10.4K | 0.00% | — | 10.4K | — | 10.4K | PN | Delaware | 2022-09-26 | ↗ |
| 33 | Juniper Multi-Strategy Fund, L.P. | 10.4K | 0.00% | 10.4K | — | 10.4K | — | PN | Delaware | 2022-09-26 | ↗ |
| 34 | Macquarie Investment Management Group Limited | 528.00 | 0.00% | 528.00 | — | 528.00 | — | CO | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.44
Bearish
Ratio by volume
3.00
Bullish
Buys
11
Sells
25
Shares acquired
424.5K
Shares disposed
133.0K
Cash buys
—
Cash sales
25.00
Net activity
+291,425
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 8,962 | 38.00 | 340.6K | 185,095 | D | ↗ |
| 2026-03-03 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 2,149 | 37.78 | 81.2K | 60,097 | D | ↗ |
| 2026-03-03 | Mackin James P | Officer | S-Sale | D | Common Stock | 17,887 | 37.78 | 675.7K | 947,275 | D | ↗ |
| 2026-03-03 | Horton Amy | Officer | S-Sale | D | Common Stock | 901 | 37.78 | 34.0K | 139,088 | D | ↗ |
| 2026-03-03 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 3,843 | 37.78 | 145.2K | 194,057 | D | ↗ |
| 2026-03-03 | Davis John E | Officer | S-Sale | D | Common Stock | 4,573 | 37.78 | 172.7K | 230,794 | D | ↗ |
| 2026-03-03 | Berry Lance A | Officer | S-Sale | D | Common Stock | 6,316 | 37.78 | 238.6K | 210,827 | D | ↗ |
| 2026-03-02 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,513 | 38.02 | 57.5K | 40,408 | D | ↗ |
| 2026-03-02 | Mackin James P | Officer | S-Sale | D | Common Stock | 14,911 | 38.02 | 567.0K | 848,214 | D | ↗ |
| 2026-03-02 | Horton Amy | Officer | S-Sale | D | Common Stock | 641 | 38.02 | 24.4K | 132,514 | D | ↗ |
| 2026-03-02 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 2,183 | 38.02 | 83.0K | 170,105 | D | ↗ |
| 2026-03-02 | Davis John E | Officer | S-Sale | D | Common Stock | 2,784 | 38.02 | 105.9K | 206,522 | D | ↗ |
| 2026-03-02 | Berry Lance A | Officer | S-Sale | D | Common Stock | 5,178 | 38.02 | 196.9K | 176,269 | D | ↗ |
| 2026-02-24 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,259 | 35.69 | 44.9K | 41,921 | D | ↗ |
| 2026-02-24 | Mackin James P | Officer | S-Sale | D | Common Stock | 13,936 | 35.69 | 497.4K | 766,095 | D | ↗ |
| 2026-02-24 | Horton Amy | Officer | S-Sale | D | Common Stock | 830 | 35.69 | 29.6K | 127,497 | D | ↗ |
| 2026-02-24 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 1,668 | 35.69 | 59.5K | 152,203 | D | ↗ |
| 2026-02-24 | Davis John E | Officer | S-Sale | D | Common Stock | 2,075 | 35.69 | 74.1K | 188,868 | D | ↗ |
| 2026-02-24 | Berry Lance A | Officer | S-Sale | D | Common Stock | 4,485 | 35.69 | 160.1K | 143,965 | D | ↗ |
| 2026-02-23 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 2,423 | 37.59 | 91.1K | 43,180 | D | ↗ |
| 2026-02-23 | Mackin James P | Officer | S-Sale | D | Common Stock | 20,962 | 37.59 | 787.9K | 780,031 | D | ↗ |
| 2026-02-23 | Horton Amy | Officer | S-Sale | D | Common Stock | 1,731 | 37.59 | 65.1K | 128,327 | D | ↗ |
| 2026-02-23 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 3,079 | 37.59 | 115.7K | 153,871 | D | ↗ |
| 2026-02-23 | Davis John E | Officer | S-Sale | D | Common Stock | 3,773 | 37.59 | 141.8K | 190,943 | D | ↗ |
| 2026-02-23 | Berry Lance A | Officer | S-Sale | D | Common Stock | 4,981 | 37.59 | 187.2K | 148,450 | D | ↗ |
| 2025-12-31 | Stanton Marshall S. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-31 | Holloway Jean F | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-31 | Davis John E | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-15 | Davis John E | Officer | S-Sale | D | Common Stock | 5,000 | 45.11 | 225.6K | 193,842 | D | ↗ |
| 2025-12-08 | Horton Amy | Officer | S-Sale | D | Common Stock | 4,572 | 44.42 | 203.1K | 130,058 | D | ↗ |
| 2025-12-03 | Mackin James P | Officer | M-Exempt | A | Common Stock | 30,921 | 29.62 | 915.9K | 831,914 | D | ↗ |
| 2025-12-03 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 2,048 | 45.30 | 92.8K | 161,360 | D | ↗ |
| 2025-12-02 | Mackin James P | Officer | M-Exempt | D | Stock Options (Right to buy) | 30,921 | 29.62 | 915.9K | 0 | D | ↗ |
| 2025-12-01 | Horton Amy | Officer | G-Gift | D | Common Stock | 750 | 0.00 | — | 134,630 | D | ↗ |
| 2025-11-21 | Stanton Marshall S. | Officer | M-Exempt | A | Common Stock | 20,301 | 18.44 | 374.4K | 65,054 | D | ↗ |
| 2025-11-20 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,355 | 44.28 | 60.0K | 44,753 | D | ↗ |
| 2025-11-18 | Hoff Elizabeth A | Director | S-Sale | D | Common Stock | 4,200 | 45.10 | 189.4K | 27,189 | D | ↗ |
| 2025-11-17 | Horton Amy | Officer | S-Sale | D | Common Stock | 6,000 | 45.73 | 274.4K | 135,380 | D | ↗ |
| 2025-11-17 | Holloway Jean F | Officer | M-Exempt | D | Stock Options (Right to buy) | 6,394 | 29.62 | 189.4K | 0 | D | ↗ |
| 2025-11-17 | Davis John E | Officer | M-Exempt | D | Stock Options (Right to buy) | 6,394 | 29.62 | 189.4K | 0 | D | ↗ |
| 2025-11-14 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 6,393 | 45.00 | 287.7K | 163,408 | D | ↗ |
| 2025-11-14 | Davis John E | Officer | S-Sale | D | Common Stock | 6,393 | 44.67 | 285.6K | 198,842 | D | ↗ |
| 2025-11-13 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 4,993 | 45.86 | 229.0K | 56,641 | D | ↗ |
| 2025-11-13 | Mackin James P | Officer | S-Sale | D | Common Stock | 34,210 | 45.86 | 1.57M | 800,993 | D | ↗ |
| 2025-11-13 | Horton Amy | Officer | S-Sale | D | Common Stock | 3,482 | 45.86 | 159.7K | 141,380 | D | ↗ |
| 2025-11-13 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 5,761 | 45.86 | 264.2K | 163,408 | D | ↗ |
| 2025-11-13 | Davis John E | Officer | S-Sale | D | Common Stock | 6,563 | 45.86 | 301.0K | 198,842 | D | ↗ |
| 2025-11-11 | Holloway Jean F | Officer | M-Exempt | D | Stock Options (Right to buy) | 10,000 | 11.03 | 110.3K | 0 | D | ↗ |
| 2025-11-10 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 2,566 | 44.62 | 114.5K | 61,634 | D | ↗ |
| 2025-11-10 | Mackin James P | Officer | S-Sale | D | Common Stock | 17,580 | 44.62 | 784.4K | 835,203 | D | ↗ |
| 2025-11-10 | Horton Amy | Officer | S-Sale | D | Common Stock | 1,789 | 44.62 | 79.8K | 144,862 | D | ↗ |
| 2025-11-10 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 2,960 | 44.62 | 132.1K | 169,169 | D | ↗ |
| 2025-11-10 | Davis John E | Officer | S-Sale | D | Common Stock | 3,373 | 44.62 | 150.5K | 205,405 | D | ↗ |
| 2025-08-27 | Stanton Marshall S. | Officer | M-Exempt | A | Common Stock | 18,200 | 11.03 | 200.7K | 82,400 | D | ↗ |
| 2025-08-25 | Holloway Jean F | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 11.03 | 110.3K | 0 | D | ↗ |
| 2025-08-15 | Mackin James P | Officer | S-Sale | D | Common Stock | 12,500 | 42.32 | 529.0K | 852,783 | D | ↗ |
| 2025-08-12 | Holloway Jean F | Officer | M-Exempt | D | Stock Option(Right to Buy) | 16,975 | 26.24 | 445.4K | 0 | D | ↗ |
| 2025-08-12 | Davis John E | Officer | M-Exempt | D | Stock Options (Right to buy) | 10,802 | 26.24 | 283.4K | 0 | D | ↗ |
| 2025-08-08 | Horton Amy | Officer | M-Exempt | A | Common Stock | 7,992 | 29.62 | 236.7K | 154,643 | D | ↗ |
| 2025-06-17 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 13,764 | 29.50 | 406.0K | 65,436 | D | ↗ |
| 2025-06-13 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,253 | 28.47 | 35.7K | 95,332 | D | ↗ |
| 2025-05-27 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 8,748 | 29.00 | 253.7K | 178,510 | D | ↗ |
| 2025-05-23 | SEMEDO ANTHONY B. | Director | S-Sale | D | Common Stock | 2,600 | 28.47 | 74.0K | 39,384 | D | ↗ |
| 2025-05-22 | Salveson Jon W | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 129,840 | D | ↗ |
| 2025-05-22 | SEMEDO ANTHONY B. | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 41,984 | D | ↗ |
| 2025-05-22 | Hoff Elizabeth A | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 31,389 | D | ↗ |
| 2025-05-22 | Burbank Jeffrey H | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 53,796 | D | ↗ |
| 2025-05-22 | Bullock James | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 68,647 | D | ↗ |
| 2025-05-22 | Borgstrom Marna P | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 49,088 | D | ↗ |
| 2025-05-22 | BEVEVINO DANIEL J | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 150,061 | D | ↗ |
| 2025-05-22 | ACKERMAN THOMAS F | Director | A-Award | A | Common Stock | 6,325 | 0.00 | — | 149,896 | D | ↗ |
| 2025-05-21 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 9,926 | 29.00 | 287.9K | 187,258 | D | ↗ |
| 2025-05-09 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 5,737 | 29.13 | 167.1K | 110,143 | D | ↗ |
| 2025-03-11 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 18,020 | 23.61 | 425.5K | 197,184 | D | ↗ |
| 2025-03-11 | Davis John E | Officer | M-Exempt | A | Common Stock | 15,910 | 21.55 | 342.9K | 223,878 | D | ↗ |
| 2025-03-06 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,603 | 24.80 | 39.8K | 115,880 | D | ↗ |
| 2025-03-06 | Mackin James P | Officer | M-Exempt | D | Stock Options (Right to buy) | 75,615 | 21.55 | 1.63M | 0 | D | ↗ |
| 2025-03-06 | Horton Amy | Officer | S-Sale | D | Common Stock | 1,048 | 24.80 | 26.0K | 146,651 | D | ↗ |
| 2025-03-06 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 2,124 | 24.80 | 52.7K | 196,112 | D | ↗ |
| 2025-03-06 | Davis John E | Officer | S-Sale | D | Common Stock | 2,618 | 24.80 | 64.9K | 207,968 | D | ↗ |
| 2025-03-06 | Berry Lance A | Officer | S-Sale | D | Common Stock | 4,909 | 24.80 | 121.8K | 153,431 | D | ↗ |
| 2025-03-05 | SEMEDO ANTHONY B. | Director | P-Purchase | A | Common Stock | 1,500 | 25.33 | 38.0K | 35,659 | D | ↗ |
| 2025-03-05 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 472 | 25.29 | 11.9K | 172,743 | D | ↗ |
| 2025-02-28 | Stanton Marshall S. | Officer | A-Award | A | Common Stock | 18,398 | 0.00 | — | 98,243 | D | ↗ |
| 2025-02-28 | Mackin James P | Officer | A-Award | A | Common Stock | 98,524 | 0.00 | — | 762,406 | D | ↗ |
| 2025-02-28 | Horton Amy | Officer | A-Award | A | Common Stock | 6,297 | 0.00 | — | 137,438 | D | ↗ |
| 2025-02-28 | Holloway Jean F | Officer | A-Award | A | Common Stock | 23,416 | 0.00 | — | 173,215 | D | ↗ |
| 2025-02-28 | Davis John E | Officer | A-Award | A | Common Stock | 24,301 | 0.00 | — | 184,932 | D | ↗ |
| 2025-02-28 | Berry Lance A | Officer | A-Award | A | Common Stock | 34,435 | 0.00 | — | 110,240 | D | ↗ |
| 2025-02-24 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 672 | 27.31 | 18.3K | 81,091 | D | ↗ |
| 2025-02-24 | Mackin James P | Officer | S-Sale | D | Common Stock | 4,896 | 27.31 | 133.7K | 663,882 | D | ↗ |
| 2025-02-24 | Horton Amy | Officer | S-Sale | D | Common Stock | 485 | 27.31 | 13.2K | 131,141 | D | ↗ |
| 2025-02-24 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 810 | 27.31 | 22.1K | 151,449 | D | ↗ |
| 2025-02-24 | Davis John E | Officer | S-Sale | D | Common Stock | 2,035 | 27.31 | 55.6K | 160,631 | D | ↗ |
| 2025-02-24 | Berry Lance A | Officer | S-Sale | D | Common Stock | 3,259 | 27.31 | 89.0K | 75,805 | D | ↗ |
| 2024-12-31 | Stanton Marshall S. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Holloway Jean F | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Davis John E | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-12 | Horton Amy | Officer | G-Gift | D | Common Stock | 1,100 | 0.00 | — | 134,464 | D | ↗ |
| 2024-12-11 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 4,035 | 30.25 | 122.1K | 157,897 | D | ↗ |
| 2024-12-06 | Horton Amy | Officer | S-Sale | D | Common Stock | 4,425 | 29.05 | 128.6K | 135,564 | D | ↗ |
| 2024-12-04 | GREEN ANDREW M | Officer | S-Sale | D | Common Stock | 7,618 | 30.00 | 228.5K | 33,503 | D | ↗ |
| 2024-10-01 | Horton Amy | Officer | M-Exempt | A | Common Stock | 12,430 | 21.55 | 267.9K | 152,419 | D | ↗ |
| 2024-08-26 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 3,167 | 26.55 | 84.1K | 161,932 | — | ↗ |
| 2024-08-16 | Getz Matthew A | Officer | S-Sale | D | Common Stock | 2,562 | 25.31 | 64.8K | 34,116 | — | ↗ |
| 2024-08-15 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 2,383 | 25.76 | 61.4K | 165,099 | — | ↗ |
| 2024-08-13 | SEMEDO ANTHONY B. | Director | S-Sale | D | Common Stock | 9,709 | 24.99 | 242.6K | 34,159 | — | ↗ |
| 2024-05-30 | Salveson Jon W | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 123,515 | — | ↗ |
| 2024-05-30 | SEMEDO ANTHONY B. | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 43,868 | — | ↗ |
| 2024-05-30 | Hoff Elizabeth A | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 25,064 | — | ↗ |
| 2024-05-30 | Burbank Jeffrey H | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 47,471 | — | ↗ |
| 2024-05-30 | Bullock James | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 62,322 | — | ↗ |
| 2024-05-30 | Borgstrom Marna P | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 42,763 | — | ↗ |
| 2024-05-30 | BEVEVINO DANIEL J | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 143,736 | — | ↗ |
| 2024-05-30 | ACKERMAN THOMAS F | Director | A-Award | A | Common Stock | 6,289 | 0.00 | — | 143,571 | — | ↗ |
| 2024-05-10 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 1,250 | 23.42 | 29.3K | 167,482 | — | ↗ |
| 2024-05-09 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 979 | 23.79 | 23.3K | 168,732 | — | ↗ |
| 2024-03-20 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 2,183 | 20.39 | 44.5K | 83,296 | — | ↗ |
| 2024-03-15 | GREEN ANDREW M | Officer | S-Sale | D | Common Stock | 1,462 | 20.00 | 29.2K | 41,121 | — | ↗ |
| 2024-03-14 | GREEN ANDREW M | Officer | S-Sale | D | Common Stock | 3,994 | 20.00 | 79.9K | 42,583 | — | ↗ |
| 2024-03-12 | Getz Matthew A | Officer | S-Sale | D | Common Stock | 5,000 | 19.94 | 99.7K | 43,536 | — | ↗ |
| 2024-03-05 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,506 | 18.72 | 28.2K | 85,438 | — | ↗ |
| 2024-03-05 | Maney Rochelle L. | Officer | S-Sale | D | Common Stock | 1,157 | 18.72 | 21.7K | 46,569 | — | ↗ |
| 2024-03-05 | Mackin James P | Officer | S-Sale | D | Common Stock | 13,996 | 18.72 | 262.0K | 706,038 | — | ↗ |
| 2024-03-05 | Horton Amy | Officer | S-Sale | D | Common Stock | 1,152 | 18.72 | 21.6K | 139,957 | — | ↗ |
| 2024-03-05 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 2,380 | 18.72 | 44.6K | 169,669 | — | ↗ |
| 2024-03-05 | Getz Matthew A | Officer | S-Sale | D | Common Stock | 1,157 | 18.72 | 21.7K | 48,503 | — | ↗ |
| 2024-03-05 | GREEN ANDREW M | Officer | S-Sale | D | Common Stock | 1,160 | 18.72 | 21.7K | 46,577 | — | ↗ |
| 2024-03-05 | Davis John E | Officer | S-Sale | D | Common Stock | 2,022 | 18.72 | 37.9K | 165,637 | — | ↗ |
| 2024-03-01 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,506 | 18.72 | 28.2K | 85,479 | — | ↗ |
| 2024-03-01 | Maney Rochelle L. | Officer | A-Award | A | Common Stock | 3,578 | 0.00 | — | 47,726 | — | ↗ |
| 2024-03-01 | Mackin James P | Officer | A-Award | A | Common Stock | 28,618 | 0.00 | — | 720,034 | — | ↗ |
| 2024-03-01 | Horton Amy | Officer | A-Award | A | Common Stock | 3,578 | 0.00 | — | 141,109 | — | ↗ |
| 2024-03-01 | Holloway Jean F | Officer | A-Award | A | Common Stock | 5,724 | 0.00 | — | 172,091 | — | ↗ |
| 2024-03-01 | Getz Matthew A | Officer | A-Award | A | Common Stock | 3,578 | 0.00 | — | 49,693 | — | ↗ |
| 2024-03-01 | GREEN ANDREW M | Officer | A-Award | A | Common Stock | 3,578 | 0.00 | — | 47,737 | — | ↗ |
| 2024-03-01 | Davis John E | Officer | A-Award | A | Common Stock | 5,724 | 0.00 | — | 167,712 | — | ↗ |
| 2024-02-27 | Tyrs Florian | Officer | S-Sale | D | Common Stock | 339 | 19.83 | 6.7K | 21,558 | — | ↗ |
| 2024-02-27 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 465 | 19.83 | 9.2K | 81,261 | — | ↗ |
| 2024-02-27 | Maney Rochelle L. | Officer | S-Sale | D | Common Stock | 370 | 19.83 | 7.3K | 44,148 | — | ↗ |
| 2024-02-27 | Mackin James P | Officer | S-Sale | D | Common Stock | 4,837 | 19.83 | 95.9K | 690,940 | — | ↗ |
| 2024-02-27 | Horton Amy | Officer | S-Sale | D | Common Stock | 325 | 19.83 | 6.4K | 137,563 | — | ↗ |
| 2024-02-27 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 485 | 19.83 | 9.6K | 166,367 | — | ↗ |
| 2024-02-27 | Getz Matthew A | Officer | S-Sale | D | Common Stock | 325 | 19.83 | 6.4K | 46,082 | — | ↗ |
| 2024-02-27 | GREEN ANDREW M | Officer | S-Sale | D | Common Stock | 421 | 19.83 | 8.4K | 44,123 | — | ↗ |
| 2024-02-27 | Davis John E | Officer | S-Sale | D | Common Stock | 584 | 19.83 | 11.6K | 161,988 | — | ↗ |
| 2024-02-26 | Tyrs Florian | Officer | S-Sale | D | Common Stock | 893 | 20.27 | 18.1K | 21,897 | — | ↗ |
| 2024-02-26 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 1,600 | 20.27 | 32.4K | 72,489 | — | ↗ |
| 2024-02-26 | Maney Rochelle L. | Officer | S-Sale | D | Common Stock | 1,185 | 20.27 | 24.0K | 39,197 | — | ↗ |
| 2024-02-26 | Mackin James P | Officer | S-Sale | D | Common Stock | 18,144 | 20.27 | 367.8K | 650,297 | — | ↗ |
| 2024-02-26 | Horton Amy | Officer | S-Sale | D | Common Stock | 1,186 | 20.27 | 24.0K | 132,418 | — | ↗ |
| 2024-02-26 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 1,566 | 20.27 | 31.7K | 166,810 | — | ↗ |
| 2024-02-26 | Getz Matthew A | Officer | S-Sale | D | Common Stock | 1,185 | 20.27 | 24.0K | 40,123 | — | ↗ |
| 2024-02-26 | GREEN ANDREW M | Officer | S-Sale | D | Common Stock | 1,185 | 20.27 | 24.0K | 38,848 | — | ↗ |
| 2024-02-26 | Davis John E | Officer | S-Sale | D | Common Stock | 1,904 | 20.27 | 38.6K | 162,519 | — | ↗ |
| 2024-02-23 | Tyrs Florian | Officer | A-Award | A | Common Stock | 6,537 | 0.00 | — | 22,790 | — | ↗ |
| 2024-02-23 | THOMSON ROBERT C | Officer | A-Award | A | Common Stock | 8,165 | 0.00 | — | 13,291 | — | ↗ |
| 2024-02-23 | Stanton Marshall S. | Officer | A-Award | A | Common Stock | 5,386 | 0.00 | — | 74,089 | — | ↗ |
| 2024-02-23 | Maney Rochelle L. | Officer | A-Award | A | Common Stock | 7,893 | 0.00 | — | 37,016 | — | ↗ |
| 2024-02-23 | Mackin James P | Officer | A-Award | A | Common Stock | 89,001 | 0.00 | — | 628,037 | — | ↗ |
| 2024-02-23 | Horton Amy | Officer | A-Award | A | Common Stock | 7,893 | 0.00 | — | 130,238 | — | ↗ |
| 2024-02-23 | Holloway Jean F | Officer | A-Award | A | Common Stock | 19,610 | 0.00 | — | 151,468 | — | ↗ |
| 2024-02-23 | Getz Matthew A | Officer | A-Award | A | Common Stock | 9,250 | 0.00 | — | 37,942 | — | ↗ |
| 2024-02-23 | GREEN ANDREW M | Officer | A-Award | A | Common Stock | 3,366 | 0.00 | — | 40,033 | — | ↗ |
| 2024-02-23 | Davis John E | Officer | A-Award | A | Common Stock | 19,734 | 0.00 | — | 147,911 | — | ↗ |
| 2024-02-23 | Berry Lance A | Officer | A-Award | A | Common Stock | 37,000 | 0.00 | — | 79,064 | — | ↗ |
| 2024-02-20 | Tyrs Florian | Officer | S-Sale | D | Common Stock | 249 | 18.87 | 4.7K | 16,253 | — | ↗ |
| 2024-02-20 | Maney Rochelle L. | Officer | S-Sale | D | Common Stock | 407 | 18.87 | 7.7K | 29,123 | — | ↗ |
| 2024-02-20 | Mackin James P | Officer | M-Exempt | A | Common Stock | 59,225 | 16.30 | 965.4K | 611,105 | — | ↗ |
| 2024-02-20 | Horton Amy | Officer | S-Sale | D | Common Stock | 366 | 18.87 | 6.9K | 122,345 | — | ↗ |
| 2024-02-20 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 1,192 | 18.87 | 22.5K | 131,858 | — | ↗ |
| 2024-02-20 | Getz Matthew A | Officer | S-Sale | D | Common Stock | 366 | 18.87 | 6.9K | 28,692 | — | ↗ |
| 2024-02-20 | Davis John E | Officer | S-Sale | D | Common Stock | 496 | 18.87 | 9.4K | 128,177 | — | ↗ |
| 2024-01-02 | Holloway Jean F | Officer | S-Sale | D | Common Stock | 21,229 | 18.00 | 382.1K | 133,520 | — | ↗ |
| 2024-01-02 | Davis John E | Officer | S-Sale | D | Common Stock | 13,562 | 18.00 | 244.1K | 128,733 | — | ↗ |
| 2023-12-31 | Stanton Marshall S. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Holloway Jean F | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Davis John E | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-15 | Horton Amy | Officer | S-Sale | D | Common Stock | 14,397 | 19.00 | 273.5K | 124,040 | — | ↗ |
| 2023-12-06 | Horton Amy | Officer | A-Award | A | Common Stock | 20,191 | 17.83 | 360.0K | 124,040 | — | ↗ |
| 2023-12-06 | Berry Lance A | Officer | A-Award | A | Stock Option (Right to Buy) | 93,633 | 17.83 | 1.67M | 93,633 | — | ↗ |
| 2023-11-27 | Horton Amy | Officer | S-Sale | D | Common Stock | 2,101 | 17.34 | 36.4K | 105,599 | — | ↗ |
| 2023-08-08 | Tyrs Florian | Officer | A-Award | A | Common Stock | 2,107 | 16.79 | 35.4K | 16,502 | — | ↗ |
| 2023-06-23 | Tyrs Florian | Officer | — | I | Common Stock | 0 | 0.00 | — | 2,483 | — | ↗ |
| 2023-06-09 | THOMSON ROBERT C | Officer | A-Award | A | Common Stock | 11,490 | 15.49 | 178.0K | 11,490 | — | ↗ |
| 2023-06-08 | THOMSON ROBERT C | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-07 | Getz Matthew A | Officer | S-Sale | D | Common Stock | 6,329 | 15.88 | 100.5K | 30,387 | — | ↗ |
| 2023-06-06 | Salveson Jon W | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 117,226 | — | ↗ |
| 2023-06-06 | SEMEDO ANTHONY B. | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 37,579 | — | ↗ |
| 2023-06-06 | Maier Dennis B | Officer | S-Sale | D | Common Stock | 378 | 15.34 | 5.8K | 34,724 | — | ↗ |
| 2023-06-06 | Hoff Elizabeth A | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 18,775 | — | ↗ |
| 2023-06-06 | Burbank Jeffrey H | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 41,182 | — | ↗ |
| 2023-06-06 | Bullock James | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 56,033 | — | ↗ |
| 2023-06-06 | Borgstrom Marna P | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 36,474 | — | ↗ |
| 2023-06-06 | BEVEVINO DANIEL J | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 137,447 | — | ↗ |
| 2023-06-06 | ACKERMAN THOMAS F | Director | A-Award | A | Common Stock | 9,709 | 0.00 | — | 137,282 | — | ↗ |
| 2023-03-02 | Stanton Marshall S. | Officer | S-Sale | D | Common Stock | 907 | 13.41 | 12.2K | 52,077 | — | ↗ |
| 2023-03-02 | Maney Rochelle L. | Officer | S-Sale | D | Common Stock | 821 | 13.41 | 11.0K | 29,530 | — | ↗ |
| 2023-03-02 | Maier Dennis B | Officer | S-Sale | D | Common Stock | 1,121 | 13.41 | 15.0K | 50,978 | — | ↗ |
| 2023-03-02 | Mackin James P | Officer | S-Sale | D | Common Stock | 9,990 | 13.41 | 134.0K | 551,880 | — | ↗ |
Executive team
Top executives
EBIT / Employee
16.7K
Shares Outstanding
48.50M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 835.1K | — | 5.01M | — | 991.4K | 49.6K | 6.88M | 72.74% | ↗ |
| 2 | 2025 | Lance A. Berry, Executive Vice President, Chief Operating Officer, Chief Financial Officer, and Treasurer | 526.4K | — | 1.96M | — | 400.2K | 90.5K | 2.98M | 65.84% | ↗ |
| 3 | 2025 | John E. Davis, Senior Vice President, Chief Commercial Officer | 441.1K | — | 1.23M | — | 261.8K | 20.2K | 1.96M | 63.07% | ↗ |
| 4 | 2025 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 438.4K | — | 1.19M | — | 260.2K | 21.0K | 1.91M | 62.32% | ↗ |
| 5 | 2025 | Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer | 443.9K | — | 935.0K | — | 263.5K | 18.0K | 1.66M | 56.31% | ↗ |
| 6 | 2024 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 806.9K | — | 3.61M | — | 1.05M | 48.0K | 5.51M | 65.46% | ↗ |
| 7 | 2024 | Lance A. Berry, Executive Vice President, Chief Operating Officer, Chief Financial Officer, and Treasurer | 500.0K | — | 1.50M | — | 390.0K | 184.1K | 2.57M | 58.27% | ↗ |
| 8 | 2024 | Lance A. Berry, Executive Vice President, Chief Financial Officer | 500.0K | — | 1.50M | — | 390.0K | 184.1K | 2.57M | 58.27% | ↗ |
| 9 | 2024 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 425.6K | — | 795.0K | — | 276.7K | 18.1K | 1.52M | 52.46% | ↗ |
| 10 | 2024 | John E. Davis, Senior Vice President, Chief Commercial Officer | 406.9K | — | 800.0K | — | 264.5K | 20.2K | 1.49M | 53.64% | ↗ |
| 11 | 2024 | Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer | 409.6K | — | 600.0K | — | 266.2K | 17.8K | 1.29M | 46.38% | ↗ |
| 12 | 2023 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 775.9K | — | 801.9K | — | 1.55M | 46.9K | 3.18M | 25.25% | ↗ |
| 13 | 2023 | Lance A, Berry, Executive Vice President, Chief Financial Officer | 38.4K | 100.0K | 750.0K | 750.0K | — | — | 1.64M | 91.56% | ↗ |
| 14 | 2023 | Lance A. Berry, Executive Vice President, Chief Operating Officer, Chief Financial Officer, and Treasurer | 38.4K | 100.0K | 750.0K | 750.0K | — | — | 1.64M | 91.56% | ↗ |
| 15 | 2023 | Lance A. Berry, Executive Vice President, Chief Financial Officer | 38.4K | 100.0K | 750.0K | 750.0K | — | — | 1.64M | 91.56% | ↗ |
| 16 | 2023 | D. Ashley Lee, Executive Vice President, Chief Financial Officer | 495.1K | — | 247.8K | — | 594.1K | 38.9K | 1.38M | 18.01% | ↗ |
| 17 | 2023 | Amy D. Horton, Vice President, Chief Accounting Officer | 329.3K | — | 440.7K | — | 263.5K | 28.4K | 1.06M | 41.50% | ↗ |
| 18 | 2023 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 411.2K | — | 152.3K | — | 411.2K | 18.9K | 993.7K | 15.33% | ↗ |
| 19 | 2023 | John E. Davis, Senior Vice President, Chief Commercial Officer | 391.2K | — | 151.4K | — | 391.2K | 19.6K | 953.4K | 15.88% | ↗ |
| 20 | 2023 | Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer | 395.7K | — | 132.5K | — | 395.7K | 18.1K | 942.0K | 14.06% | ↗ |
| 21 | 2022 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 749.6K | — | 3.42M | 2.17M | 835.1K | 44.4K | 7.22M | 77.43% | ↗ |
| 22 | 2022 | D. Ashley Lee, Executive Vice President, Chief Financial Officer, and Chief Operating Officer | 478.3K | — | 949.2K | 615.9K | 319.7K | 27.4K | 2.39M | 65.47% | ↗ |
| 23 | 2022 | D. Ashley Lee, Executive Vice President, Chief Financial Officer | 478.3K | — | 888.9K | 615.9K | 319.7K | 27.4K | 2.33M | 64.58% | ↗ |
| 24 | 2022 | John E. Davis, Senior Vice President, Global Sales and Marketing | 379.8K | — | 663.0K | 405.0K | 211.6K | 18.5K | 1.68M | 63.65% | ↗ |
| 25 | 2022 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 397.3K | — | 620.5K | 409.2K | 221.3K | 18.1K | 1.67M | 61.79% | ↗ |
| 26 | 2022 | John E. Davis, Senior Vice President, Chief Commercial Officer | 379.8K | — | 613.7K | 405.0K | 211.6K | 18.5K | 1.63M | 62.55% | ↗ |
| 27 | 2022 | Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer | 384.2K | — | 624.0K | 369.5K | 214.0K | 17.3K | 1.61M | 61.74% | ↗ |
| 28 | 2021 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 727.8K | 80.0K | 2.15M | 824.8K | 799.9K | 43.4K | 4.63M | 64.33% | ↗ |
| 29 | 2021 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 385.8K | 21.2K | 766.5K | 169.8K | 212.0K | 22.7K | 1.58M | 59.34% | ↗ |
| 30 | 2021 | D. Ashley Lee, Executive Vice President, Chief Financial Officer, and Chief Operating Officer | 464.4K | 30.6K | 496.4K | 194.3K | 306.2K | 34.2K | 1.53M | 45.26% | ↗ |
| 31 | 2021 | D. Ashley Lee, Executive Vice President, Chief Financial Officer | 464.4K | 30.6K | 472.3K | 194.3K | 306.2K | 34.2K | 1.50M | 44.38% | ↗ |
| 32 | 2021 | John E. Davis, Senior Vice President, Global Sales and Marketing | 368.8K | 20.3K | 386.0K | 150.0K | 202.6K | 17.9K | 1.15M | 46.79% | ↗ |
| 33 | 2021 | John E. Davis, Senior Vice President, Chief Commercial Officer | 368.8K | 20.3K | 367.1K | 150.0K | 202.6K | 17.9K | 1.13M | 45.89% | ↗ |
| 34 | 2021 | Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer | 295.7K | 16.9K | 449.5K | — | 168.8K | 16.3K | 947.2K | 47.46% | ↗ |
| 35 | 2020 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 605.8K | 441.6K | 1.58M | 745.6K | — | 44.5K | 3.42M | 68.03% | ↗ |
| 36 | 2020 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 384.0K | 169.1K | 421.5K | 183.3K | — | 26.0K | 1.18M | 51.09% | ↗ |
| 37 | 2020 | D. Ashley Lee, Executive Vice President, Chief Financial Officer, and Chief Operating Officer | 384.0K | 169.1K | 421.5K | 183.3K | — | 26.0K | 1.18M | 51.09% | ↗ |
| 38 | 2020 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 319.0K | 117.0K | 338.8K | 146.7K | — | 40.2K | 961.7K | 50.48% | ↗ |
| 39 | 2020 | John E. Davis, Senior Vice President, Global Sales and Marketing | 306.9K | 111.9K | 323.9K | 140.0K | — | 17.6K | 900.3K | 51.53% | ↗ |
| 40 | 2020 | Michael S. Simpson, Senior Vice President, Regulatory Affairs and Quality Assurance | 295.8K | 107.8K | 309.0K | 133.3K | — | 16.5K | 862.4K | 51.29% | ↗ |
| 41 | 2019 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 688.6K | — | 4.42M | 709.3K | 597.0K | 39.9K | 6.45M | 79.46% | ↗ |
| 42 | 2019 | D. Ashley Lee, Executive Vice President, Chief Financial Officer, and Chief Operating Officer | 435.2K | 22.6K | 850.0K | 175.0K | 226.4K | 28.4K | 1.74M | 58.99% | ↗ |
| 43 | 2019 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 435.2K | 22.6K | 850.0K | 175.0K | 226.4K | 28.4K | 1.74M | 58.99% | ↗ |
| 44 | 2019 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 361.5K | 15.7K | 693.4K | 146.7K | 156.7K | 17.2K | 1.39M | 60.39% | ↗ |
| 45 | 2019 | Michael S. Simpson, Senior Vice President, Regulatory Affairs and Quality Assurance | 336.3K | 75.0K | 666.6K | 133.3K | 145.8K | 14.2K | 1.37M | 58.34% | ↗ |
| 46 | 2019 | John E. Davis, Senior Vice President, Global Sales and Marketing | 348.9K | — | 693.6K | 146.7K | 151.2K | 14.7K | 1.36M | 62.01% | ↗ |
| 47 | 2018 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 660.0K | 132.0K | 1.27M | 633.7K | 494.0K | 39.3K | 3.23M | 58.98% | ↗ |
| 48 | 2018 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 418.9K | 50.3K | 366.7K | 183.3K | 188.1K | 54.4K | 1.26M | 43.59% | ↗ |
| 49 | 2018 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 346.3K | 34.6K | 320.0K | 160.0K | 129.6K | 41.4K | 1.03M | 46.52% | ↗ |
| 50 | 2018 | James M. McDermid, Senior Vice President, Chief Human Resources Officer | 332.1K | 332.1K | 266.7K | 133.3K | 124.3K | 36.5K | 926.1K | 43.19% | ↗ |
| 51 | 2018 | John E. Davis, Senior Vice President, Global Sales and Marketing | 334.2K | 33.4K | 266.7K | 133.3K | 125.1K | 30.7K | 923.4K | 43.32% | ↗ |
| 52 | 2017 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 640.0K | 108.8K | 1.01M | 523.2K | 414.9K | 36.2K | 2.74M | 56.17% | ↗ |
| 53 | 2017 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 402.8K | 72.5K | 297.0K | 153.2K | 184.3K | 24.3K | 1.13M | 39.70% | ↗ |
| 54 | 2017 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 329.8K | 59.4K | 245.7K | 126.7K | 113.2K | 18.4K | 893.2K | 41.70% | ↗ |
| 55 | 2017 | John E. Davis, Senior Vice President, Global Sales and Marketing | 321.4K | 32.1K | 235.4K | 121.5K | 122.5K | 8.1K | 841.0K | 42.43% | ↗ |
| 56 | 2017 | William R. Matthews, Senior Vice President, Operations, Quality and Regulatory | 348.1K | 31.3K | 204.7K | 105.6K | 119.5K | 16.6K | 825.9K | 37.58% | ↗ |
| 57 | 2016 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 620.0K | 93.0K | 870.1K | 435.6K | 477.1K | 36.6K | 2.53M | 51.56% | ↗ |
| 58 | 2016 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 387.3K | 69.7K | 306.1K | 134.0K | 238.4K | 20.6K | 1.16M | 38.07% | ↗ |
| 59 | 2016 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 314.1K | 49.5K | 221.5K | 95.5K | 145.0K | 17.5K | 843.0K | 37.60% | ↗ |
| 60 | 2016 | William R. Matthews, Senior Vice President, Operations, Quality and Regulatory | 338.0K | 30.4K | 190.8K | 95.5K | 156.0K | 17.1K | 827.8K | 34.58% | ↗ |
| 61 | 2016 | John E. Davis, Senior Vice President, Global Sales and Marketing | 309.0K | 46.4K | 190.8K | 95.5K | 158.5K | 5.3K | 805.4K | 35.54% | ↗ |
| 62 | 2015 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 600.0K | 72.0K | 678.3K | 569.00 | 288.1K | 74.0K | 2.05M | 33.08% | ↗ |
| 63 | 2015 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 376.0K | 45.1K | 271.3K | 135.8K | 180.5K | 19.9K | 1.03M | 39.58% | ↗ |
| 64 | 2015 | David P. Lang, Senior Vice President, International Sales & Marketing | 190.4K | 15.1K | 162.8K | 81.5K | 60.5K | 328.5K | 838.8K | 29.12% | ↗ |
| 65 | 2015 | Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 226.5K | 68.2K | 211.8K | 95.7K | 72.8K | 25.6K | 700.6K | 43.89% | ↗ |
| 66 | 2015 | Jean F. Holloway, Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | 226.5K | 68.2K | 211.8K | 95.7K | 72.8K | 25.6K | 700.6K | 43.89% | ↗ |
| 67 | 2015 | Scott B. Capps Vice President, Clinical Research | 291.5K | 11.7K | 162.8K | 81.5K | 93.3K | 5.3K | 646.0K | 37.81% | ↗ |
| 68 | 2015 | David C. Gale, Vice President, Research & Development | 254.4K | 20.4K | 162.8K | 81.5K | 81.4K | 4.7K | 605.1K | 40.37% | ↗ |
| 69 | 2014 | J. Patrick Mackin, Chairman, President and Chief Executive Officer | 197.7K | 223.9K | 2.55M | 1.67M | 64.9K | 62.7K | 4.76M | 88.47% | ↗ |
| 70 | 2014 | Steven G. Anderson, Former Executive Chairman; Former President and Chief Executive Officer | 683.0K | 82.0K | 830.8K | 170.0K | 222.8K | 31.0K | 2.11M | 47.42% | ↗ |
| 71 | 2014 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 376.0K | 45.1K | 332.3K | 68.0K | 122.6K | 18.5K | 962.6K | 41.59% | ↗ |
| 72 | 2014 | Jeffrey W. Burris, Former Vice President and General Counsel | 190.5K | 15.2K | 232.6K | 47.6K | 41.4K | 135.6K | 663.0K | 42.27% | ↗ |
| 73 | 2014 | David M. Fronk Vice President, Regulatory Affairs and Quality Assurance | 283.0K | — | 232.6K | 47.6K | 61.5K | 5.2K | 630.0K | 44.48% | ↗ |
| 74 | 2014 | Scott B. Capps Vice President, Clinical Research | 283.0K | 22.6K | 199.4K | 40.8K | 61.5K | 5.1K | 612.5K | 39.22% | ↗ |
| 75 | 2014 | Bruce G. Anderson, Vice President, U.S. Sales and Global Marketing | 273.0K | 21.8K | 199.4K | 40.8K | 59.4K | 3.5K | 597.9K | 40.18% | ↗ |
| 76 | 2013 | Steven G. Anderson, Former Executive Chairman; Former President and Chief Executive Officer | 664.0K | 79.7K | 500.8K | 105.8K | 268.7K | 129.4K | 1.75M | 34.70% | ↗ |
| 77 | 2013 | Steven G. Anderson Chairman of the Board, President, and Chief Executive Officer | 664.0K | 79.7K | 500.8K | 105.8K | 268.7K | 129.4K | 1.75M | 34.70% | ↗ |
| 78 | 2013 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 365.0K | 43.8K | 200.3K | 42.3K | 147.7K | 18.2K | 817.4K | 29.69% | ↗ |
| 79 | 2013 | Jeffrey W. Burris Vice President and General Counsel | 293.0K | 23.4K | 140.2K | 29.6K | 79.1K | 5.1K | 570.5K | 29.78% | ↗ |
| 80 | 2013 | Jeffrey W. Burris, Former Vice President and General Counsel | 293.0K | 23.4K | 140.2K | 29.6K | 79.1K | 5.1K | 570.5K | 29.78% | ↗ |
| 81 | 2013 | David M. Fronk Vice President, Regulatory Affairs and Quality Assurance | 275.0K | 22.0K | 140.2K | 29.6K | 74.2K | 5.1K | 546.2K | 31.10% | ↗ |
| 82 | 2013 | Scott B. Capps Vice President, Clinical Research | 270.0K | 21.6K | 120.2K | 25.4K | 72.8K | 5.0K | 515.1K | 28.27% | ↗ |
| 83 | 2012 | Steven G. Anderson Chairman of the Board, President, and Chief Executive Officer | 656.9K | 78.8K | 454.6K | 111.2K | 354.3K | 43.8K | 1.71M | 33.16% | ↗ |
| 84 | 2012 | Steven G. Anderson, Former Executive Chairman; Former President and Chief Executive Officer | 656.9K | 78.8K | 454.6K | 111.2K | 354.3K | 43.8K | 1.71M | 33.16% | ↗ |
| 85 | 2012 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 361.4K | 43.4K | 181.8K | 44.5K | 194.9K | 20.2K | 846.3K | 26.74% | ↗ |
| 86 | 2012 | Gerald B. Seery Former Senior Vice President, Sales and Marketing | 290.0K | 23.2K | 197.3K | 31.1K | 104.3K | 22.1K | 674.4K | 33.87% | ↗ |
| 87 | 2012 | Jeffrey W. Burris Vice President and General Counsel | 290.0K | 23.2K | 127.3K | 31.1K | 104.3K | 11.2K | 587.1K | 26.99% | ↗ |
| 88 | 2012 | Jeffrey W. Burris, Former Vice President and General Counsel | 290.0K | 23.2K | 127.3K | 31.1K | 104.3K | 11.2K | 587.1K | 26.99% | ↗ |
| 89 | 2012 | David M. Fronk Vice President, Regulatory Affairs and Quality Assurance | 269.4K | 21.6K | 127.3K | 31.1K | 96.9K | 5.0K | 551.3K | 28.74% | ↗ |
| 90 | 2012 | Scott B. Capps Vice President, Clinical Research | 265.0K | 21.2K | 90.9K | 22.2K | 95.3K | 4.9K | 499.5K | 22.65% | ↗ |
| 91 | 2011 | Steven G. Anderson Chairman of the Board, President, and Chief Executive Officer | 637.8K | 76.5K | 402.8K | 399.6K | 252.6K | 33.6K | 1.83M | 43.89% | ↗ |
| 92 | 2011 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 361.4K | 43.4K | 162.1K | 160.9K | 143.2K | 14.0K | 884.9K | 36.50% | ↗ |
| 93 | 2011 | Albert E. Heacox, Ph.D. Former Senior Vice President, Research and Development | 290.0K | 23.2K | 148.7K | 111.8K | 76.6K | 17.3K | 667.6K | 39.02% | ↗ |
| 94 | 2011 | Jeffrey W. Burris Vice President and General Counsel | 290.0K | 23.2K | 112.6K | 111.8K | 76.6K | 2.5K | 616.6K | 36.39% | ↗ |
| 95 | 2011 | Gerald B. Seery Senior Vice President, Sales and Marketing | 290.0K | 23.2K | 112.6K | 111.8K | 76.6K | 1.7K | 615.9K | 36.44% | ↗ |
| 96 | 2011 | Gerald B. Seery Former Senior Vice President, Sales and Marketing | 290.0K | 23.2K | 112.6K | 111.8K | 76.6K | 1.7K | 615.9K | 36.44% | ↗ |
| 97 | 2010 | Steven G. Anderson Chairman of the Board, President, and Chief Executive Officer | 619.2K | 88.2K | 262.1K | 280.8K | 195.7K | 116.4K | 1.58M | 34.40% | ↗ |
| 98 | 2010 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 350.9K | 47.4K | 104.8K | 112.3K | 110.9K | 12.7K | 739.1K | 29.38% | ↗ |
| 99 | 2010 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 281.6K | 25.3K | 73.4K | 78.6K | 59.3K | 2.5K | 520.7K | 29.19% | ↗ |
| 100 | 2010 | Albert E. Heacox, Ph.D. Former Senior Vice President, Research and Development | 281.6K | 25.3K | 73.4K | 78.6K | 59.3K | 2.5K | 520.7K | 29.19% | ↗ |
| 101 | 2010 | Jeffrey W. Burris Vice President and General Counsel | 275.0K | 26.1K | 74.6K | 78.6K | 57.9K | 2.5K | 514.7K | 29.76% | ↗ |
| 102 | 2010 | Gerald B. Seery Senior Vice President, Sales and Marketing | 275.0K | 24.8K | 73.4K | 78.6K | 57.9K | 1.7K | 511.4K | 29.73% | ↗ |
| 103 | 2010 | Gerald B. Seery Former Senior Vice President, Sales and Marketing | 275.0K | 24.8K | 73.4K | 78.6K | 57.9K | 1.7K | 511.4K | 29.73% | ↗ |
| 104 | 2009 | Steven G. Anderson Chairman of the Board, President, and Chief Executive Officer | 619.2K | 92.9K | 175.5K | 300.0K | 212.8K | 58.5K | 1.50M | 31.68% | ↗ |
| 105 | 2009 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 350.9K | 44.7K | 103.3K | 90.0K | 120.6K | 15.0K | 724.5K | 26.67% | ↗ |
| 106 | 2009 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 281.6K | 23.9K | 62.0K | 54.0K | 64.5K | 4.9K | 490.9K | 23.62% | ↗ |
| 107 | 2009 | Albert E. Heacox, Ph.D. Former Senior Vice President, Research and Development | 281.6K | 23.9K | 62.0K | 54.0K | 64.5K | 4.9K | 490.9K | 23.62% | ↗ |
| 108 | 2009 | Gerald B. Seery Senior Vice President, Sales and Marketing | 275.0K | 24.8K | 62.0K | 54.0K | 63.0K | 4.1K | 482.8K | 24.01% | ↗ |
| 109 | 2009 | David M. Fronk Vice President, Regulatory Affairs and Quality Assurance | 254.4K | 24.2K | 41.3K | 36.0K | 58.3K | 4.9K | 419.1K | 18.45% | ↗ |
| 110 | 2008 | Steven G. Anderson Chairman of the Board of Directors, President, and Chief Executive Officer | 618.2K | 88.2K | 234.7K | 194.5K | 334.7K | 34.0K | 1.55M | 27.70% | ↗ |
| 111 | 2008 | Steven G. Anderson Chairman of the Board, President, and Chief Executive Officer | 618.2K | 88.2K | 96.3K | 276.0K | 334.7K | 34.0K | 1.49M | 24.94% | ↗ |
| 112 | 2008 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 349.4K | 42.1K | 56.6K | 162.4K | 189.7K | 14.8K | 815.0K | 26.87% | ↗ |
| 113 | 2008 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 280.8K | 22.2K | 34.0K | 97.4K | 88.8K | 4.6K | 527.7K | 24.90% | ↗ |
| 114 | 2008 | Gerald B. Seery Senior Vice President, Sales and Marketing | 271.6K | 21.7K | 34.0K | 97.4K | 80.6K | 4.5K | 509.7K | 25.78% | ↗ |
| 115 | 2008 | David M. Fronk Vice President, Regulatory Affairs and Quality Assurance | 252.4K | 17.2K | 22.7K | 65.0K | 68.8K | 4.6K | 430.6K | 20.35% | ↗ |
| 116 | 2007 | Steven G. Anderson Chairman of the Board, President, and Chief Executive Officer | 600.0K | 63.0K | 270.8K | 250.5K | 345.3K | 28.4K | 2.29M | 22.75% | ↗ |
| 117 | 2007 | Steven G. Anderson Chairman of the Board of Directors, President, and Chief Executive Officer | 600.0K | 63.0K | 203.0K | 111.2K | 345.3K | 28.4K | 2.08M | 15.07% | ↗ |
| 118 | 2007 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 340.0K | 35.7K | 155.5K | 147.4K | 195.7K | 4.5K | 878.8K | 34.47% | ↗ |
| 119 | 2007 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 265.7K | 16.3K | 85.7K | 88.4K | 104.7K | 4.4K | 565.1K | 30.81% | ↗ |
| 120 | 2007 | Gerald B. Seery Senior Vice President, Sales and Marketing | 250.0K | 15.3K | 80.7K | 88.4K | 94.1K | 4.5K | 533.1K | 31.73% | ↗ |
| 121 | 2007 | David M. Fronk Vice President, Regulatory Affairs and Quality Assurance | 240.0K | 12.6K | 64.7K | 59.0K | 85.9K | 4.4K | 466.5K | 26.51% | ↗ |
| 122 | 2006 | Steven G. Anderson Chairman of the Board of Directors, President, and Chief Executive Officer | 600.0K | 54.0K | 284.7K | 75.4K | 299.8K | 4.1K | 1.72M | 20.95% | ↗ |
| 123 | 2006 | D. Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 340.0K | 30.6K | 163.4K | 118.2K | 169.9K | 4.4K | 826.5K | 34.07% | ↗ |
| 124 | 2006 | David Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 340.0K | 30.6K | 163.4K | 118.2K | 169.9K | 4.4K | 826.5K | 34.07% | ↗ |
| 125 | 2006 | Gerald B. Seery Senior Vice President, Sales and Marketing | 250.0K | — | 48.8K | 52.1K | 112.3K | 69.8K | 533.0K | 18.93% | ↗ |
| 126 | 2006 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 265.7K | 12.6K | 84.7K | 34.2K | 87.4K | 4.4K | 488.9K | 24.32% | ↗ |
| 127 | 2006 | David M. Fronk Vice President, Regulatory Affairs and Quality Assurance | 240.0K | 10.3K | 65.9K | 33.9K | 70.8K | 4.4K | 425.3K | 23.48% | ↗ |
| 128 | 2005 | Gerald B. Seery Senior Vice President, Sales and Marketing | 308.5K | — | — | — | — | 57.7K | 366.2K | 0.00% | ↗ |
| 129 | 2004 | James C. Vander Wyk, Ph.D. Former Vice President, Product Integrity | 228.6K | — | — | — | — | 409.6K | 638.2K | 0.00% | ↗ |
| 130 | 2004 | Steven G. Anderson Chairman of the Board of Directors, President, and Chief Executive Officer | 600.0K | — | — | 10.0K | — | 4.0K | 604.0K | 1.66% | ↗ |
| 131 | 2004 | David Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 300.7K | — | 138.2K | 15.0K | — | 4.0K | 442.9K | 34.59% | ↗ |
| 132 | 2004 | Kirby S. Black, Ph.D. Former Senior Vice President, Research and Development | 240.2K | — | — | — | — | 138.9K | 379.1K | 0.00% | ↗ |
| 133 | 2004 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 252.9K | — | 34.6K | 15.0K | — | 3.8K | 291.2K | 17.01% | ↗ |
| 134 | 2004 | David M. Fronk Vice President, Clinical Research | 214.5K | — | 34.6K | 10.0K | — | 3.9K | 253.0K | 17.61% | ↗ |
| 135 | 2003 | Steven G. Anderson Chairman of the Board of Directors, President and Chief Vice President, Chief Financial Kirby S. Black, Ph.D Senior Vice President, Research Albert E. Heacox, Ph.D James C. Vander Wyk, Ph.D Vice President, Product Integrity | 600.0K | — | — | — | — | 2.3K | 602.3K | 0.00% | ↗ |
| 136 | 2003 | Steven G. Anderson Chairman of the Board of Directors, President, and Chief Executive Officer | 600.0K | — | — | 45.0K | — | 2.3K | 602.3K | 7.47% | ↗ |
| 137 | 2003 | David Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 261.3K | — | — | — | — | 2.8K | 264.2K | 0.00% | ↗ |
| 138 | 2003 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 253.0K | — | — | — | — | 2.8K | 255.8K | 0.00% | ↗ |
| 139 | 2003 | Kirby S. Black, Ph.D. Former Senior Vice President, Research and Development | 253.0K | — | — | — | — | 2.0K | 255.0K | 0.00% | ↗ |
| 140 | 2003 | James C. Vander Wyk, Ph.D. Former Vice President, Product Integrity | 240.0K | — | — | — | — | 5.0K | 245.0K | 0.00% | ↗ |
| 141 | 2003 | David M. Fronk Vice President, Clinical Research | 214.5K | — | — | — | — | 3.0K | 217.5K | 0.00% | ↗ |
| 142 | 2002 | Steven G. Anderson Chairman of the Board of Directors, President, and Chief Executive Officer | 600.0K | 300.0K | — | 50.0K | — | 30.0K | 930.0K | 5.38% | ↗ |
| 143 | 2002 | Steven G. Anderson Chairman of the Board of Directors, President and Chief Vice President, Chief Financial Kirby S. Black, Ph.D Senior Vice President, Research Albert E. Heacox, Ph.D James C. Vander Wyk, Ph.D Vice President, Product Integrity | 600.0K | 300.0K | — | — | — | 30.0K | 930.0K | 0.00% | ↗ |
| 144 | 2002 | Kirby S. Black, Ph.D. Former Senior Vice President, Research and Development | 225.0K | 120.0K | — | 48.3K | — | 21.0K | 366.0K | 13.19% | ↗ |
| 145 | 2002 | Albert E. Heacox, Ph.D. Senior Vice President, Research and Development | 225.0K | 120.0K | — | 24.9K | — | 16.2K | 361.2K | 6.88% | ↗ |
| 146 | 2002 | David Ashley Lee Executive Vice President, Chief Operating Officer, and Chief Financial Officer | 220.0K | 120.0K | — | 72.5K | — | 5.0K | 345.0K | 21.01% | ↗ |
| 147 | 2002 | James C. Vander Wyk, Ph.D. Former Vice President, Product Integrity | 240.0K | 60.0K | — | 34.7K | — | 21.0K | 321.0K | 10.81% | ↗ |
| 148 | 2002 | David M. Fronk Vice President, Clinical Research | 195.0K | 80.0K | — | 48.5K | — | 8.4K | 283.4K | 17.11% | ↗ |
| 149 | 2001 | Steven G. Anderson Chairman of the Board of Directors, President and Chief Vice President, Chief Financial Kirby S. Black, Ph.D Senior Vice President, Research Albert E. Heacox, Ph.D James C. Vander Wyk, Ph.D Vice President, Product Integrity | 600.0K | 300.0K | — | — | — | 47.7K | 947.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Patrick Mackin | Chairman, President & Chief Executive Officer | 2M | male |
| Lance A. Berry | EVice President, Chief Operating Officer, Chief Financial Officer & Treasurer | 1M | male |
| John E. Davis | Senior Vice President & Chief Commercial Officer | 723.1K | male |
| Jean F. Holloway | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | 719.6K | female |
| Simona Zannetti | Senior Vice President of Clinical Research & Chief Medical Officer | 693.6K | — |
| Marshall S. Stanton | Senior Vice President of Clinical Research & Chief Medical Officer | 693.6K | — |
| Amy D. Horton | Vice President & Chief Accounting Officer | 621.3K | female |
| Andrew Green | Senior Vice President of Regulatory & Quality | — | male |
| Matthew A. Getz | Vice President of Human Resources & Chief Human Resources Officer | — | male |
| Robert C. Thomson | Vice President of Research & Development | — | — |
| Jason D. Asper | Senior Vice President and Chief Strategy & Digital Officer | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-10-09 | 2025-11-18 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2023-07-14 | 2023-08-21 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-06-13 | 2023-07-11 | Josh Gottheimer | NJ05 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AORT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
